BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community

Harmony Biosciences (HRMY)Harmony BiosciencesCompany update

PLYMOUTH MEETING, Pa. -- Sept. 22, 2026 -- Harmony Biosciences today recognized World Narcolepsy Day, observed annually on September 22, by reflecting on nearly a decade of commitment to the narcolepsy and broader sleep-wake community. Since its founding in 2017, Harmony has worked alongside

Related news

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

NBIXNeurocrine Biosciences2026-10-16 12:30 EST

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

AXSMAxsome2026-09-21 11:00 EST

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

NGENNervGen Pharma2026-09-09 11:30 EST

NervGen to Host Inaugural R&D Day on September 30, 2026

TEVATeva Pharmaceutical Industries2026-08-31 20:07 EST

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

View all latest news

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

HRMYHarmony Biosciences2026-11-04 12:30 EST

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

HRMYHarmony Biosciences2026-10-20 12:05 EST

Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026

HRMYHarmony Biosciences2026-10-12 11:00 EST

Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

HRMYHarmony Biosciences2026-09-22 12:30 EST

Harmony Biosciences Recognizes World Narcolepsy Day 2026, Reflecting on Nearly a Decade of Commitment to the Sleep Community

Stock data

Close
32.47 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States